<DOC>
	<DOCNO>NCT01296672</DOCNO>
	<brief_summary>The investigator propose novel method improve prostate cancer screen PSA , use 3-month treatment finasteride , drug use treat Benign Prostatic Hyperplasia ( BPH ) proven reduce man 's risk develop prostate cancer . The investigator also examine three additional promising test may improve diagnosis prostate cancer .</brief_summary>
	<brief_title>3 Month Finasteride Challenge Test Can Significantly Improve Performance Screening Prostate Cancer</brief_title>
	<detailed_description>The primary goal proposal determine 5-alpha reductase 'challenge ' improves screen performance PSA DRE men schedule prostate biopsy . Currently high PSA level lead recommendation prostate biopsy , cause hundred thousand unnecessary biopsy annually U.S. We show three-month treatment finasteride men high PSA level well predict man prostate biopsy . PSA performance finasteride 'challenge ' also compare new test prostate cancer . Finasteride supply Merck Company , Incorporated .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Finasteride</mesh_term>
	<criteria>1 . Risk prostate cancer 2060 % calculated online Prostate Cancer Prevention Trial ( PCPT ) prostate cancer risk calculator . ( www.prostatecancerriskcalculator.com ) . PSA value must obtain within 3 month prior study entry . A description frequency individual population provide Specific Aim 2 2 . Patient recommend undergo plan prostate biopsy . 3 . Patient willing delay prostate biopsy 3month finasteride v placebo treatment . 4 . No allergy finasteride five alpha reductase inhibitor . 5 . Patient willing take finasteride v placebo 5 mg orally daily 3month treatment period . 6 . Age 55 old . ( This age select PCPT risk calculator valid age range . ) 1 . Risk cancer great 60 % le 20 % . 2 . Prior history prostate cancer . 3 . Prior treatment finasteride dutasteride past 6 month 4 . Younger age 55 .</criteria>
	<gender>Male</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Finasteride</keyword>
	<keyword>Placebo</keyword>
	<keyword>Prostate cancer</keyword>
	<keyword>Prostate Specific Antigen ( PSA )</keyword>
	<keyword>Men intermediate risk prostate cancer</keyword>
	<keyword>Men schedule prostate biopsy</keyword>
</DOC>